Company Description
Heart Test Laboratories, Inc., doing business as HeartSciences, is a medical technology company focuses on applying AI-based technology to an ECG to expand and improve an ECG's clinical utility.
It is developing AI-ECG solutions, a proprietary algorithm designed to detect impaired cardiac relaxation, or cardiac dysfunction, caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG, a resting 12-lead ECG that will incorporate its AI-ECG algorithm that provides diagnostic information related to cardiac dysfunction and conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis.
The company is doing business as HeartSciences. Heart Test Laboratories, Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
Country | United States |
Founded | 2007 |
IPO Date | Jun 15, 2022 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 15 |
CEO | Andrew Simpson |
Contact Details
Address: 550 Reserve Street, Suite 360 Southlake, Texas 76092 United States | |
Phone | 682-237-7781 |
Website | heartsciences.com |
Stock Details
Ticker Symbol | HSCS |
Exchange | NASDAQ |
Fiscal Year | May - April |
Reporting Currency | USD |
IPO Price | $4.25 |
CIK Code | 0001468492 |
CUSIP Number | 42254E104 |
ISIN Number | US42254E1047 |
Employer ID | 26-1344466 |
SIC Code | 3842 |
Key Executives
Name | Position |
---|---|
Andrew Simpson | Chief Executive Officer, President and Chairman of the Board of Directors |
Danielle Watson | Chief Financial Officer and Treasurer |
Mark T. Hilz | Chief Operating Officer, Secretary and Director |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 21, 2024 | 8-K/A | [Amend] Current report |
Oct 18, 2024 | 8-K | Current Report |
Sep 27, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Sep 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Sep 18, 2024 | DEF 14A | Other definitive proxy statements |
Sep 12, 2024 | 8-K | Current Report |
Sep 12, 2024 | 10-Q | Quarterly Report |
Sep 10, 2024 | 8-K | Current Report |
Aug 21, 2024 | 8-K | Current Report |
Jul 29, 2024 | 8-K | Current Report |